Décès du second patient de l’essai de faisabilité - ACHAT - OC 124€
La société annonçait hier après marché que le deuxième patient implanté d’une prothèse CARMAT en août dernier venait de décéder après près de neuf mois de survie. Le communiqué fait état d’une dérive fonctionnelle de la prothèse qui a conduit à la volonté d’implanter un second cœur artificiel par l’équipe médico-chirurgicale. Des complications suites à cette implantation ont entrainé le décès de ce second patient. L’étude de faisabilité en cours incluant 4 patients n’est pas remise en cause, les deux premiers patients ayant atteint le critère primaire d’évaluation. Nous n’avons à ce stade aucune nouvelle spécifique sur le troisième patient implanté. Nous maintenons notre objectif de cours à 124€ et notre recommandation à ACHAT.Carmat is focused on the research and development of an innovative product in the medical sector, developing an orthotopic and biocompatible artificial heart which is completely implantable, as well as its electrical power supply system and remote diagnosis system. Co. is developing a long-term therapeutic solution for patients who suffer from advanced bi-ventricular heart failure and who are not eligible for cardiac transplantation and who have exhausted all drug possibilties. Co. is still in the phase of research and development and thus do not generate any revenues.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.